Lotte Spekhorst from the University Medical Center Utrecht, Utrecht, The Netherlands presents their Original Article published in Allergy:
Spekhorst, LS, Bakker, D, Drylewicz, J, et al. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Allergy. 2022.
Research highlights:
• Dose reduction was successful in a subgroup of controlled atopic dermatitis (AD) patients by using a patient-centered dupilumab dosing regimen.
• Despite significantly lower dupilumab levels, eczema and severity score (EASI)-score and disease severity biomarkers (TARC/CCL17 and PARC/CCL18) in group B (Q4W) and C (Q6W/Q8W) remained low and stable.
• These findings are the first step towards personalized dupilumab treatment for controlled AD patients in clinical practice.
Follow Allergy on:
Facebook:
Twitter:
LinkedIn:
Instagram:
Like, share and comment on our videos, thank you.
